Supplier News Breaks Archives
Clapton joins government affairs team at PhRMA
February 27th, 2014
WASHINGTON – Charles Clapton has been appointed senior vice president of federal advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA).
PhRMA said this week that Clapton, who will be responsible for leading PhRMA's federal government affairs initiatives and advancing its legislative agenda, is slated to start in the post on March 17.
Clapton will report to Chip Davis, executive vice president of advocacy and member relations at PhRMA.
"Chuck is a dynamic advocate and an expert on the policy issues facing the biopharmaceutical sector and the patients we serve," stated John Castellani, president and chief executive officer of PhRMA. "He will make important contributions to our work with policymakers on promoting research and innovation and making progress for patients."
Clapton joins PhRMA from the international law firm HoganLovells, where as a partner he represented health care clients on legislative and regulatory matters. Before that, he worked for 17 years on Capitol Hill, where he held several leadership positions on the House Energy & Commerce Committee, Ways & Means Committee and the Office of the Speaker, as well as the Senate Health, Education, Labor and Pensions Committee.
"Chuck's experience, reputation and results-oriented focus during his distinguished career on Capitol Hill will be tremendous assets to PhRMA and its members as he leads our federal advocacy efforts," Davis commented.
PhRMA noted that during his time with the House and Senate, Clapton worked on reimbursement and coverage efforts, including the Medicare Modernization Act that created the Medicare Part D drug program. He also has extensive experience with policy issues related to Food and Drug Administration review and approval of new medicines, the distribution and use of non-FDA-approved drugs, and other key patient safety matters.
"I am incredibly excited to join the PhRMA team," Clapton stated. "While the industry faces significant challenges, PhRMA member companies are developing new treatments that will revolutionize how we treat diseases like cancer and diabetes. I look forward to representing PhRMA members and assisting their efforts to help patients improve access to new treatments and support policies foster the continuing development of new treatments and cures."